Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized radioiodine therapy for metastatic differentiated thyroid cancer with iodine-124 PET dosimetry
2024-516273-80-00Phase 2Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- May 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iodine-131 in well-differentiated thyroid cancer (WDTC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Complete response rate in soft-tissue metastases. Planned start May 2021; status: authorised.
02
Drugs
iodine-131
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on 2024-516273-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516273-80-00.